Tern portfolio company Talking Medicines reports record revenue bookings

Tern Plc (LON:ERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has noted that Talking Medicines Limited, a company in which Tern currently holds 23.8% of the equity, has announced an update on its Q1 2024 performance, extracts of which are set out below.

Extracts from the Talking Medicines announcement:

“Talking Medicines, a pioneering leader in healthcare intelligence leveraging advanced data science and artificial intelligence, is pleased to announce a strong start to 2024, marked by record revenue bookings and significant advancements in its innovative platform, Talking Medicines Drug-GPT.

In the first quarter of 2024, Talking Medicines achieved significant success with its Talking Medicines Drug-GPT platform, which aims to revolutionise access to intelligence on pharmaceutical medicine brands and disease areas.  This innovative technology has garnered substantial interest from leading global healthcare advertising agencies, who recognise its potential to transform strategies for pharmaceutical clients.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Tern plc

More articles like this

Tern plc

How AI-human synergy is rewriting the rules of Pharma Marketing

AI is no longer a futuristic concept in Pharma Marketing—it’s a powerful force already reshaping strategy, precision, and personalisation at scale. But its real magic happens when it partners with human expertise, unlocking smarter, more responsive